CompletedPhase 2NCT00939523
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Studying Pituitary adenoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cedars-Sinai Medical Center
- Principal Investigator
- Odelia Cooper, MD, M.DCedars-Sinai Medical Center
- Intervention
- Lapatinib(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2018
Study locations (3)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00939523 on ClinicalTrials.govOther trials for Pituitary adenoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07446036Prediction Model for Postoperative Headache After Transsphenoidal Pituitary SurgeryBeijing Tiantan Hospital
- RECRUITINGNCT06973824A Twenty-years' Experience in Pituitary Disease.Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE4NCT06679816Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine TumorsBeijing Tiantan Hospital
- RECRUITINGPHASE4NCT06353529Postop Pain Management in Pituitary Tumour PatientsHamilton Health Sciences Corporation
- RECRUITINGNCT06705036Differential Study of Invasive Pituitary Adenomas in the Sellar and Cavernous Sinus RegionsShanghai Zhongshan Hospital
- RECRUITINGNANCT07247526Effect of Foot Bath on Anxiety and Physiological ParametersTrakya University
- ACTIVE NOT RECRUITINGNCT06664190Pre-operative Surgical Difficulty Stratification Using Predicted Tumor Perfusion and ConsistencyHuashan Hospital
- ACTIVE NOT RECRUITINGPHASE1NCT03465618A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain TumorsMemorial Sloan Kettering Cancer Center